These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31182534)

  • 21. Solithromycin for the treatment of community-acquired bacterial pneumonia.
    Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
    Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
    Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model.
    Maglio D; Sun HK; Patel T; Banevicius MA; Nightingale CH; Arya A; Wang G; Chen Z; Phan LT; Nicolau DP
    Int J Antimicrob Agents; 2014 Jun; 43(6):540-6. PubMed ID: 24703590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Zhou YF; Liu P; Dai SH; Sun J; Liu YH; Liao XP
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
    Wicha WW; Craig WA; Andes D
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solithromycin: A novel ketolide antibiotic.
    Buege MJ; Brown JE; Aitken SL
    Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against
    Li X; Chen Y; Xu X; Li Y; Fan Y; Liu X; Bian X; Wu H; Zhao X; Feng M; Guo B; Zhang J
    Front Pharmacol; 2021; 12():658558. PubMed ID: 34017256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment
    VanScoy BD; Lakota EA; Conde H; McCauley J; Friedrich L; Steenbergen JN; Ambrose PG; Bhavnani SM
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32284378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism, Excretion, and Mass Balance of Solithromycin in Humans.
    MacLauchlin C; Schneider SE; Keedy K; Fernandes P; Jamieson BD
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29507061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics/Pharmacodynamics of Pulmonary Delivery of Colistin against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Cheah SE; Zhao J; Chen K; Wang J; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
    Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
    Tessier PR; Mattoes HM; Dandekar PK; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Jan; 49(1):188-94. PubMed ID: 15616295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.
    Farrell DJ; Mendes RE; Jones RN
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2432-4. PubMed ID: 25605359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo Pharmacokinetics/Pharmacodynamics Profiles for Appropriate Doses of Cefditoren pivoxil against S. pneumoniae in Murine Lung-Infection Model.
    Igarashi Y; Kojima N; Takemura W; Liu X; Morita T; Mizukami Y; Enoki Y; Taguchi K; Yokoyama Y; Nakamura T; Matsumoto K
    Pharm Res; 2023 Jul; 40(7):1789-1797. PubMed ID: 37253866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations.
    Zhanel GG; Johanson C; Hisanaga T; Mendoza C; Laing N; Noreddin A; Wierzbowski A; Hoban DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):1072-7. PubMed ID: 15531596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Jan; 50(1):243-9. PubMed ID: 16377693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.